Proteinuria in a placebo-controlled study of basic fibroblast growth factor for intermittent claudication

Leslie T. Cooper, William R. Hiatt, Mark A. Creager, Judith G. Regensteiner, Ward Casscells, Jeffrey M. Isner, John P. Cooke, Alan T. Hirsch

Research output: Contribution to journalArticlepeer-review

44 Scopus citations


Intermittent claudication is the most common symptom of peripheral arterial disease (PAD), in part due to an inadequate rise in limb blood flow with exercise. Claudication causes a severe impairment in functional capacity and quality of life in over 3 million Americans. Basic fibroblast growth factor (bFGF) stimulates angiogenesis in vivo and improves limb blood flow in several animal models of hindlimb ischemia. However, the relative safety and efficacy of angiogenic molecules in the treatment of claudication has not been fully evaluated in prospective, blinded clinical trials. In this study, a randomized, double-blind, placebo-controlled, phase II trial of recombinant human bFGF for the treatment of intermittent claudication was performed. bFGF was administered weekly by intravenous infusions of 2 μg/kg for 6 sequential weeks (total dose 12 μg/kg). The primary efficacy endpoint was change in peak walking time (PWT) on a graded exercise treadmill protocol. Secondary efficacy endpoints included changes in functional status as measured by validated questionnaires. The study was stopped prematurely after treatment of the first 24 subjects due to proteinuria in five of the 16 subjects who received systemic bFGF, which exceeded 1000 mg/24 h in four of these five subjects. The small sample size limited evaluation of the predefined efficacy endpoints; however, there was no significant difference between the treatment and control groups for any of the measures of efficacy. In conclusion, intravenous administration of bFGF delivered at low doses weekly for 6 weeks was associated with a high rate of severe proteinuria. It is speculated that bFGF-related proteinuria in this study was primarily related to the systemic route of administration and the frequent dosing schedule. Future clinical trials of bFGF protein should carefully monitor renal function and consider alternative dosing schedules and drug administration routes.

Original languageEnglish (US)
Pages (from-to)235-239
Number of pages5
JournalVascular Medicine
Issue number4
StatePublished - 2001
Externally publishedYes


  • Angiogenesis
  • Claudication
  • Growth substances
  • Trials


Dive into the research topics of 'Proteinuria in a placebo-controlled study of basic fibroblast growth factor for intermittent claudication'. Together they form a unique fingerprint.

Cite this